Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

AHS Cancer Control Alberta: Clinical Trials & FDA Approval Profile

AHS Cancer Control Alberta (Global / Institutional) sponsors 40 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 25 active protocols (15 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)27.5%
Median Closed Enrollment vs National (145 pts)22 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for AHS Cancer Control Alberta
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)40
Active Pipeline (Recruiting Now)25 (15)
Completed vs Stopped Early4 / 11 (27.5%)
Median Closed Actual Enrollment22 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With AHS Cancer Control Alberta
Hospital Research SiteLocationShared Protocols
Cross Cancer InstituteEdmonton, Alberta29
Arthur J E Child Comprehensive Cancer CentreCalgary, Alberta5

Explore interactive annual charts and M&A subsidiary rollups in the AHS Cancer Control Alberta Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI